Professor KWOK_LEUNG CHEUNG's Outputs (2)

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial (2016)
Journal Article
Robertson, J. F., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., Ruiz-Borrego, M., Shao, Z., Noguchi, S., Rowbottom, J., Stuart, M., Grinsted, L. M., Fazal, M., & Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/S0140-6736%2816%2932389-3

Background

Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free surviva... Read More about Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer (2016)
Journal Article
Hunt, K. K., Karakas, C., Ha, M. J., Biernacka, A., Yi, M., Sahin, A., Adjapong, O., Hortobogyi, G. N., Bondy, M. L., Thompson, P. A., Cheung, K. L., Ellis, I. O., Bacus, S., Symmans, W. F., Do, K.-A., & Keyomarsi, K. (2017). Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 23(12), 2991-3002. https://doi.org/10.1158/1078-0432.ccr-16-2217

Background: Low-molecular-weight-cyclin E (LMW-E) detected by Western blot, predicts for reduced breast cancer survival, however, it is impractical for clinical use. LMW-E lacks a nuclear localization signal which leads to accumulation in the cytopla... Read More about Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.